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Abstract
Background: The Mtb72f subunit vaccine for tuberculosis, currently in clinical trials, is hoped to provide improved 
protection compared to the current BCG vaccine. It is not clear, however, whether Mtb72f would be equally protective 
in the different human populations suffering from a high burden of tuberculosis. Previous work by Hebert and 
colleagues demonstrated that the PPE18 protein of Mtb72f had significant variability in a sample of clinical M. 
tuberculosis isolates. However, whether this variation might impact the efficacy of Mtb72f in the context of the 
microbial and host immune system interactions remained to be determined. The present study assesses Mtb72f's 
predicted efficacy in people with different DRB1 genotypes to predict whether the vaccine will protect against diverse 
clinical strains of M. tuberculosis in a diverse host population.
Results: We evaluated the binding of epitopes in the vaccine to different alleles of the human DRB1 Class II MHC 
protein using freely available epitope prediction programs and compared protein sequences from clinical isolates to 
the sequences included in the Mtb72f vaccine. This analysis predicted that the Mtb72f vaccine would be less effective 
for several DRB1 genotypes, due either to limited vaccine epitope binding to the DRB1 proteins or to binding primarily 
by unconserved PPE18 epitopes. Furthermore, we found that these less-protective DRB1 alleles are found at a very high 
frequency in several populations with a high burden of tuberculosis.
Conclusion: Although the Mtb72f vaccine candidate has shown promise in animal and clinical trials thus far, it may not 
be optimally effective in some genotypic backgrounds. Due to variation in both M. tuberculosis protein sequences and 
epitope-binding capabilities of different HLA alleles, certain human populations with a high burden of tuberculosis 
may not be optimally protected by the Mtb72f vaccine. The efficacy of the Mtb72f vaccine should be further examined 
in these particular populations to determine whether additional protective measures might be necessary for these 
regions.
Background
Although the Bacille Calmette Guérin (BCG) vaccine for
tuberculosis (TB) is the most widely used vaccine world-
wide, TB continues to be a tremendous public health
problem [1]. A third of the world's population is esti-
mated to be infected with Mycobacterium tuberculosis
and 2-3 million people die of the disease each year [1,2].
Key among the reasons for the unabated spread of TB is
the inability of the BCG vaccine to provide adequate pro-
tection against pulmonary TB in adults, the most conta-
gious form of TB [1]. Developing an improved vaccine for
TB, whether a replacement for BCG, a booster to the
existing vaccine, or a vaccine specifically directed against
latent TB, is of crucial importance in the battle to defeat
the disease [3,4].
While several TB vaccine candidates have demon-
strated protective efficacy in animal models and have
proceeded to clinical trials in humans [1,3], even a suc-
cessful clinical trial cannot guarantee that a vaccine can
protect all members of the diverse worldwide human
population against all variants of M. tuberculosis. One
promising vaccine candidate is the Mtb72f subunit vac-
cine, a polyprotein composed of the M. tuberculosis pro-
teins PepA and PPE18 [5]. The PPE18 antigen has been
* Correspondence: zhenhua@umich.edu
1 Department of Epidemiology University of Michigan, Ann Arbor, MI 48109, 
USA
Full list of author information is available at the end of the articleBioMed Central
© 2010 McNamara et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
McNamara et al. BMC Immunology 2010, 11:18
http://www.biomedcentral.com/1471-2172/11/18
Page 2 of 12demonstrated to contain at least 10 epitopes [6] and the
vaccine has been shown to provide protection against TB
in cynomolgus monkeys [7]; it is currently under clinical
trials in humans. The peptide sequence of Mtb72f, like
that of many vaccines, is based on a laboratory strain of
the pathogen whose antigens may differ from those found
in variable clinical strains in immunologically critical
ways [8]. Furthermore, the diversity of the Human Leuko-
cyte Antigen (HLA) and other immune genes results in
variable vaccine efficacy in different individuals even in
the absence of pathogen variation [9]. While clinical trials
include individuals of many HLA genotypes, genotype
frequencies vary dramatically in different regions; geno-
types that are common in TB-endemic regions may be
underrepresented in clinical trial populations. It is there-
fore necessary to incorporate information on host and
pathogen genetic diversity in vaccine design, develop-
ment, and testing.
The PPE protein family of M. tuberculosis is a large, 69-
member protein family with a currently unknown func-
tion [10]. Previous work by Hebert and colleagues [8]
demonstrated that the PPE18 protein of Mtb72f, but not
the PepA protein, had significant variability in a sample of
clinical M. tuberculosis isolates. Such variation, however,
would be important only if the variation were in regions
of the protein that were vital for the human immune
response to M. tuberculosis. To determine whether varia-
tion in these proteins might impact the efficacy of
Mtb72f, we must consider interactions between the M.
tuberculosis proteins and the human immune system.
Of the many genes involved in the immune response,
the Major Histocompatibility Complex (MHC) genes -
HLA in humans - are among the most crucial and yet
most variable. MHC proteins present foreign peptide
epitopes from intracellular (MHC Class I) and extracellu-
lar (MHC Class II) pathogens to CD8+ cytotoxic (Class I)
or CD4+ helper (Class II) T cells to initiate the immune
response. The Mtb72f vaccine was found to stimulate
both CD4+ and CD8+ T cell-mediated responses in a
mouse model [5], and the CD4+ T cell response in partic-
ular is thought to be essential for preventing M. tubercu-
losis infection [1,2]. There are thousands of HLA alleles
[11], however, and variation in these alleles can signifi-
cantly impact individual responses to vaccination [9].
Recently, several algorithms to predict the affinity of
peptide sequences for various Class I and Class II MHC
alleles have been developed [12,13] and several have been
extensively validated [11-15]. A consensus approach
incorporating three or more programs has been shown to
increase the accuracy of MHC Class II epitope predic-
tions [15,16]. To investigate the impact of host and patho-
gen variation on TB vaccine efficacy, we have used
previously reported protein sequences from clinical iso-
lates of M. tuberculosis [8] and in silico HLA epitope pre-
diction programs to assess the protection offered by the
Mtb72f subunit vaccine against diverse strains of M.
tuberculosis in human populations suffering from a high
burden of the disease. This investigation revealed that
due to variation in both M. tuberculosis protein
sequences and epitope-binding capabilities of different
HLA alleles, certain human populations with a high bur-
den of tuberculosis may not be optimally protected by the
Mtb72f vaccine.
Results
Comparison of epitopes between the vaccine and clinical 
strains
To determine the impact of clinical strain variation on the
protection offered by the Mtb72f vaccine, we examined
the conservation of each nonamer sequence predicted to
be a binding epitope compared to the conservation of
every nonamer sequence in the vaccine. Eight epitope
prediction programs were used to determine epitopes
predicted to bind (Table 1). There was substantial varia-
tion in the number of nonamer sequences predicted to
act as epitopes for each DRB1 allele by each prediction
program (Table 2). However, when a list of all PPE18 non-
amer cores predicted to bind at least one DRB1 allele was
compiled using the epitope predictions for the five pre-
diction programs that covered the greatest number of
DRB1 alleles, 65% of these nonamers were unconserved.
This percentage was significantly greater than the 60% of
total PPE18 nonamer sequences that were unconserved
(Binomial test, p < 0.0001). We also considered individual
prediction programs' epitope binding predictions for sin-
gle DRB1 alleles. For 41 out of 56 individual DRB1 allele/
prediction program combinations, more than 60% of the
epitopes predicted to bind were unconserved; for 14 of
these, 80-100% were unconserved (Table 2). No nonamer
sequences in the PepA protein were classified as uncon-
served epitopes.
Prediction of promiscuous epitopes
As promiscuous epitopes are frequently sought for
epitope-based vaccines, we examined such epitopes,
defining them as epitopes predicted to bind at least four
of the twelve DRB1 alleles studied and classifying them as
conserved or unconserved (Table 3). In all, fifteen pro-
miscuous epitopes were predicted, ten from the PPE18
protein and five from PepA. Eight of these epitopes,
including all of the PepA epitopes, were classified as con-
served and the other seven as unconserved. Of note, the
three PPE18 epitopes predicted to bind the largest num-
bers of epitopes (9, 6, and 6, respectively) were all classi-
fied as unconserved.
Prediction of DRB1 allele binding
To find DRB1 alleles that might be especially well or
poorly covered by the Mtb72f vaccine, we summed the
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of total (Figure 1a) and conserved (Figure 1b) vaccine
epitopes predicted to bind each DRB1 allele. DRB1*0101
was consistently predicted to bind an extremely large
number of epitopes; a median of 147 total epitopes (range
26-554) and 93 conserved epitopes (range 16-356) were
predicted to bind. By contrast, DRB1 alleles 0301, 0802,
and 1301 were each predicted to bind a very small num-
ber of total or conserved vaccine epitopes. DRB1*0301
was predicted to bind a median of 11 total vaccine
epitopes (range = 0-29) and four conserved vaccine
epitopes (range = 0-22) while DRB1*0802 was predicted
to bind a median of seven total vaccine epitopes (range =
0-15) and three conserved vaccine epitopes (range = 0-9).
Finally, DRB1*1301 was predicted to bind a median of
eight total vaccine epitopes (range = 0-26) and five con-
served vaccine epitopes (range = 0-17). Similar trends
were observed when total PPE18 epitopes, conserved
PPE18 epitopes, and PepA epitopes predicted to bind
each allele were evaluated separately (data not shown).
Non-TB antigenic regions
Because the Mtb72f vaccine is a polyprotein composed of
a single continuous amino acid chain incorporating the
full PPE18 protein, the PepA protein separated into two
pieces, an N-terminal His tag, and short amino acid
insertions between the protein segments, several poten-
tial MHC Class II epitopes are found in the vaccine but
not in the native M. tuberculosis proteins [5]. If these
epitopes bound to DRB1 proteins, they could misdirect T
cells to respond to non-TB epitopes rather than to
epitopes found in the pathogen [17]. Non-pathogen
epitopes make up a relatively high proportion of the
epitopes in the Mtb72f vaccine compared to other vac-
cines, such as killed or live attenuated vaccines that do
not contain artificial epitopes, and thus these epitopes
might misdirect the immune response to Mtb72f in a
manner not seen with other vaccines. We therefore evalu-
ated the DRB1 binding of each potential MHC Class II
epitope core found in the vaccine but not in the individ-
ual proteins. The maximum median number of non-TB
vaccine epitopes predicted to bind to any of the DRB1
alleles was two (Figure 1c). Of the three DRB1 epitopes
predicted to bind the smallest number of total or con-
served vaccine epitopes (DRB1*0301, 0802, and 1301;
Figure 1a and 1b), two were predicted to bind none of the
non-TB epitopes and the third, DRB1*1301, was pre-
Table 1: Attributes of and citations for the epitope prediction programs used
Program Prediction method Unique features Source paper (number of
citations1)
URL
ARB Average relative 
binding matrices
[42] (59) [43]
MHCPred Partial least squares [33] (46) [44]
[34] (30)
[35] (30)
ProPred Matrix-based TEPITOPE matrices; 
requires key anchor 
residues
[45] (186) [41]
TEPITOPE: [30] (310)
RankPep Position Specific [23] (119) [47]
Scoring Matrices [46] (102)
NetMHCII Position Specific 
Scoring Matrices
Predicts epitopes of 
multiple lengths; uses 
SMM-align matrices
[37] (29) [48]
SVRMHC Support vector 
machine regression
[32] (16) [49]
[31] (23)
Vaxign Position Specific 
Scoring Matrices
[40] (0) [50]
NetMHCIIpan Artificial Neural 
Networks
Predicts multiple-
length epitope 
binding to every 
sequenced Class II 
allele
[11] (3) [51]
1 Citation numbers are from Google Scholar
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1c).
Alleles of concern in regions with a high burden of TB
HLA DRB1 alleles of concern were defined as DRB1
alleles predicted to bind four or fewer conserved epitopes
in the Mtb72f vaccine.  Based on these criteria, we found
that the alleles of concern were DRB1*0301, 0302, 0403,
0411, 0802, 0803, 0807, 1202, 1401, 1403, 1404, 1405, and
1504 (Table 4). Of these alleles, only four (DRB1*0803,
0807, 1401, and 1404) were predicted to bind as many or
more conserved as unconserved epitopes, while the
remaining nine were predicted to bind fewer conserved
than unconserved epitopes or (DRB1*0302) to bind no
epitopes at all. Five additional alleles (DRB1*1101, 0901,
1402, 1502, and 1602) that were not predicted to bind
particularly few conserved epitopes nevertheless bound
at least as many unconserved as conserved epitopes
(Table 4). We further examined whether any of these
alleles were predicted to bind the non-TB epitopes in the
vaccine. Although most of the alleles were not predicted
to bind any of these epitopes, DRB1*0302, 0403, and 0411
were each predicted to bind to one non-TB epitope (data
not shown).
Populations of concern for reduced vaccine efficacy
Based on the alleles of concern determined through
epitope binding predictions, we characterized each popu-
lation in the Allele*Frequencies Database from a TB-
endemic country as being of great, moderate, or lesser
concern for reduced Mtb72f vaccine efficacy. Populations
of moderate or great concern were those in which alleles
that bound relatively few conserved vaccine epitopes
were particularly common (see definitions above). The
populations of moderate concern are the Ticuna popula-
tion of Brazil; China's Shanxi Province and Maonan,
Kazak, Bai, Lahu, Naxi, Jino, and Yai ethnic minorities
throughout the country; a population in Delhi, India; the
Philippines; the Venda population of South Africa; a pop-
ulation in Bangkok, Thailand; and Vietnam. The popula-
tions of great concern are the Kaingang and East Amazon
indigenous populations of Brazil; the Xinjiang Uyghur
Autonomous Region of China as well as Yunnan Prov-
ince's Drung, Va, Lisu, Naxi, and Nu ethnic minorities;
and Indonesian Java.
Discussion
Despite the striking variation in the protective efficacy of
the BCG vaccine for TB observed among different world
populations[18], the joint impact of host and pathogen
variation on novel TB vaccine candidates has never been
characterized. Using epitope prediction programs, we
investigated the impact of clinical variations in the
Mtb72f TB vaccine components, the PPE18 and PepA
proteins, on epitope binding to alleles of the Class II HLA
DRB1 gene. We identified conserved and unconserved
promiscuous epitopes in the PPE18 and PepA proteins
using the clinical variants described previously [8] and
determined that while 60% of potential CD4+ T-cell
epitopes in the PPE18 protein were unconserved, 65% of
the actually predicted T-cell epitopes in this protein were
unconserved. We furthermore found several DRB1 alleles
that bound few vaccine epitopes overall and others that
bound predominantly unconserved or non-TB epitopes,
Table 2: Total number of PPE18 epitopes predicted to bind each allele by the five programs that predicted epitope binding 
for the largest number of DRB1 alleles and the number and percentage of unconserved epitopes
No of total predicted epitopes No of unconserved epitopes (%)
DRB1 
Allele
ARB ProPred RankPep NetMHCII NetMHCIIpan ARB ProPred RankPep NetMHCII NetMHCIIpan
0101 133 17 30 104 77 83 (62) 9 (53) 20 (67) 61 (59) 46 (60)
0301 17 8 0 0 1 13 (76) 4 (50) 0 (N/A) 0 (N/A) 1 (100)
0401 33 12 33 18 7 20 (61) 8 (67) 23 (70) 13 (72) 7 (100)
0404 47 15 5 14 10 30 (64) 10 (67) 5 (100) 14 (71) 8 (80)
0405 29 13 2 14 13 20 (69) 8 (62) 1 (50) 9 (64) 9 (69)
0701 31 7 6 16 28 22 (71) 5 (71) 4 (67) 11 (69) 19 (68)
0802 8 7 0 1 7 (87) 6 (86) 0 (N/A) 1 (100)
0901 35 3 22 21 18 (51) 3 (100) 13 (59) 14 (67)
1101 16 13 15 5 4 12 (75) 10 (77) 6 (40) 3 (60) 3 (75)
1301 7 0 1 6 (86) 0 (N/A) 1 (100)
1302 18 5 0 24 2 13 (72) 4 (80) 0 (N/A) 16 (67) 2 (100)
1501 14 10 1 12 7 10 (71) 8 (80) 1 (100) 6 (50) 5 (71)
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broader populations where the Mtb72f vaccine may not
offer maximum protection.
Our finding that 60% of potential CD4+ T-cell epitopes
in PPE18 are unconserved is consistent with previous
research that has found the PPE gene family to be partic-
ularly variable among tuberculosis isolates [19]. The sig-
nificant increase in the proportion of unconserved T-cell
epitopes among the actually predicted epitopes com-
pared to the potential epitopes (all nonamer sequences in
the vaccine) likely reflects the selective pressure that the
immune system places upon the bacterium to alter anti-
genic protein regions. Based on the clinical protein
sequences previously described [8], no potential epitopes
in the PepA protein were classified as unconserved.
Although to our knowledge no other studies have com-
pared PepA protein conservation to that of other M.
tuberculosis proteins, previous findings that PepA is
highly conserved among Mycobacterium species [20] sug-
gest that PepA may be a relatively well-conserved protein.
The high conservation of the PepA protein even under
selective pressure from the immune response may indi-
cate that little variation in this protein is compatible with
protein function, and thus PepA may be a particularly
good vaccine target [21].
We also examined the conservation of promiscuous
epitopes. Epitope promiscuity is commonly evaluated in
the generation of epitope-based vaccines [22-24], but
since they are antigenic, promiscuously binding epitopes
should be selected against by a large range of host
immune systems. We would therefore expect to find
many unconserved promiscuous epitopes. This was
found to be the case: seven of the ten promiscuous
epitopes predicted for PPE18 were unconserved. How-
ever, all five of the promiscuous PepA epitopes were con-
served, and thus these epitopes could be particularly
good candidates for epitope-based vaccines.
Although the majority of the promiscuous PPE18
epitopes identified were found to be unconserved, it is
possible that these epitopes might nevertheless provide
protection against the bacterium if they are found in
other M. tuberculosis proteins. We therefore investigated
whether these epitopes were found in two proteins
(PPE19 and PPE60) that are closely related to PPE18. This
analysis revealed that only three of the promiscuous
epitopes were present in all three proteins. The remain-
ing seven were found only in PPE18.
Our finding that three of the twelve DRB1 alleles
selected, DRB1*0301, DRB1*0802, and DRB1*1301, were
predicted to bind few total and conserved epitopes in the
Table 3: Conservation of promiscuous epitopes
Epitope core Protein DRB1 alleles predicted to 
bind
Conservation
VRAMSSLGS PPE18 0101, 0401, 0404, 0405, 0802, 
0901, 1101, 1301, 1501
Unconserved
MILIATNLL PPE18 0101, 0401, 0404, 1301, 1302, 
1501
Unconserved
MVSMANNHM PPE18 0101, 0401, 0404, 0405, 1301, 
1302
Unconserved
YVAWMSVTA PPE18 0101, 0401, 0404, 0405, 1101 Conserved
LLGQNTPAI PPE18 0101, 0401, 0404, 1301 Conserved
ILIATNLLG PPE18 0101, 0401, 0404, 1301, 1501 Unconserved
ISNMVSMAN PPE18 0101, 0401, 0404, 0405, 1101 Unconserved
LFSAASAFQ PPE18 0101, 0401, 0405, 0901 Conserved
YVMPHSPAA PPE18 0101, 0401, 0405, 0802 Unconserved
VSMTNTLSS PPE18 0101, 0401, 0404, 0405 Unconserved
VVGMNTAAS PepA 0101, 0301, 0401, 0404, 0405, 
0802, 1101, 1301, 1501
Conserved
VVLTNNHVI PepA 0101, 0405, 0701, 0802, 1101, 
1301, 1302, 1501
Conserved
VVGSAPAAS PepA 0101, 0404, 0802, 0901, 1101, 
1301
Conserved
FLGLGVVDN PepA 0101, 0401, 0405, 1101 Conserved
LRGAGGLPS PepA 0101, 0802, 1101, 1301 Conserved
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maximally protective in people who have one or more of
these alleles. By contrast, DRB1*0101 was consistently
predicted to bind far more total (median 147) and con-
served (median 93) vaccine epitopes than any other
DRB1 allele (median 16 total or 9 conserved), suggesting
that individuals with this allele might be particularly well
protected by the vaccine. DRB1*0101 is a common allele
in the US and Belgium, where Phase I clinical trials for
the Mtb72f vaccine were conducted, but unfortunately is
rarer in Brazil, China, Indonesia, and many other coun-
tries where TB is endemic according to the Allele*Fre-
quencies in Worldwide Populations database [25].
Therefore, while the vaccine may be effective in the US
and Belgium, it may not be equally effective in other
regions.
Our analysis of all the DRB1 alleles in the Allele*Fre-
quencies in WorldWide Populations database [25] that
were found to be one of the top three most common
alleles in any population in any of the twenty-two coun-
tries designated as TB high-burden countries by the
WHO [26] generated a list of the alleles of concern in
high-burden TB countries. These alleles include
DRB1*0301, 0302, 0403, 0411, 0802, 0803, 0807, 1202,
1401, 1403, 1404, 1405, and 1504. Although the epitope
predictions for these alleles should be treated with more
caution, as predictions for most could be generated by
only one or two prediction programs, the importance of
these alleles merits their consideration.
While the number of epitopes capable of binding to a
particular MHC allele does not necessarily indicate how
strong the immune response will be in that MHC back-
ground [27], the fact that many of these alleles bind very
few conserved epitopes is of concern for two reasons.
First, the analysis conducted here includes only predic-
tions of epitope binding to the MHC molecule and not
the cellular processing that must take place before MHC
presentation occurs. Because of this processing, many
potential antigenic peptides will not be generated in vivo.
For MHC alleles to which few epitopes are predicted to
bind, it is possible that none of the potentially binding
epitopes will be generated in vivo and thus that no
epitopes in the vaccine will be presented on DRB1 pro-
teins. Furthermore, for some DRB1 alleles the number of
conserved epitopes predicted to bind is much smaller
than the number of unconserved epitopes predicted to
bind. In the immune response to a vaccine or pathogen, a
single or small number of epitopes is usually immu-
nodominant [27] even though many epitopes could
potentially bind to the MHC alleles in question. For MHC
alleles that are predicted to bind many fewer conserved
than unconserved epitopes, it is likely that the immune
response to the vaccine would be dominated by responses
to unconserved epitopes and therefore would not be opti-
Figure 1 Boxplots of CD4+ T cell epitope nonamer cores (y-axis) 
in the Mtb72f vaccine predicted to bind to each of the twelve se-
lected DRB1 alleles (x-axis) by the eight chosen epitope predic-
tion programs. Epitopes found in the unmodified PepA protein but 
not in the vaccine have been excluded, as have epitopes found in the 
vaccine but not in the unmodified proteins. Boxes show the lower 
quartile, median, and upper quartile; whiskers show the minimum and 
maximum values excluding outliers (circles) and diamonds show the 
mean. The symbols next to the names of DRB1 alleles indicate the 
numbers of programs used to predict epitope binding to each allele: ! 
= 4, * = 5, # = 6, $ = 7, and + = 8. The highest outliers for alleles 0101, 
0401, and 0701 on each chart are from MHCPred. a. Total vaccine 
epitope binding predictions. b. Vaccine epitope binding predictions 
for conserved epitopes only. Conserved epitopes are defined as 
epitope nonamer cores plus N- and C-terminal pentamer flanking se-
quences that are absent or mutated in no more than two of the variant 
strains sequenced. c. Epitopes in the vaccine but not in the native 
PPE18 or PepA proteins that are predicted to bind each DRB1 allele.
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DRB1 Allele1 Median total
(conserved) epitopes
N2 Association with 
tuberculosis 
(reference)
Tuberculosis-endemic populations 
where allele is highly prevalent4
0101 122 (76) 9 NK3 Russian Chuvash, Aleuts and Tuva, Indian 
Islamic populations
0102 46 (30) 3 NK Ethiopia (Amhara)
0301 11 (4) 6 Protective [29] Brazil, northern China, Ethiopia (Oromo), 
northern and eastern India, 
northwestern Russia, Thailand 
(Bangkok), South Africa (Venda)
0302 0 (0) 1 NK South Africa (Venda)
0401 29 (15) 8 NK Chinese Inner Mongolian Evenki, Russian 
Chukchi, Eskimo, Koryak, Buryat, and 
Negidal populations
0403 11 (4) 1 NK Russian Buryat and Nganasan 
populations
0404 16 (8) 6 NK Brazil Kaingang indigenous population
0405 20 (11) 6 NK Philippines
0411 7 (3) 1 NK Brazil indigenous populations
0701 16 (9) 8 Protective [29] Brazil, Northern and Eastern China, 
Democratic Republic of the Congo, 
Ethiopia, Indonesia (Java), Russian 
Bearian Island Aleuts, Russia Chuvash, 
Russia (Siberia), Thailand (Bangkok), 
Vietnam (Hanoi)
0801 9 (7) 2 Susceptible [29] Russia (Kets)
0802 7 (3) 4 Susceptible [29] Brazil indigenous populations, Russian 
Eskimos
0803 2 (1) 1 Susceptible [52] China (Yunnan Province)
0804 7 (5) 2 NK Brazil East Amazon indigenous 
populations
0807 2 (2) 1 NK Brazil Guarani Kaiowa and Ticuna 
indigenous populations
0901 23 (10) 5 NK Brazil Southeast Caucasian population, 
China, Russia (Siberia), Thailand, Vietnam 
(Hanoi)
1001 138 (77) 1 NK Northern and eastern India, Russian 
Buryat population
1101 13 (5) 7 Susceptible [53]; 
Protective [29]
Northeast Brazil, Northern and central 
China, Democratic Republic of the 
Congo, northern India, Indonesia 
(Molucca and Nusa Tenggara), Russian 
Evenks, Nganasan, and Tuva 
populations, Zimbabwe (Harare)
1201 13 (7) 2 NK China (Southern and Harbin), northeast 
India, Russia (Siberia)
1202 8 (2) 1 NK Southern and central China, Hong Kong 
and Singapore, Indonesia, Philippines, 
Thailand, Vietnam (Hanoi)
1301 8 (5) 4 Protective [29] Brazil, China (Xinjiang), Democratic 
Republic of the Congo, India (Andhra 
Pradesh), Russia (Kets, Khanty-Mansi), 
South Africa (Venda), Zimbabwe (Harare)
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(8/13, ~62%) of the alleles of concern were predicted to
bind at least as many unconserved as conserved epitopes,
and one was predicted to bind no conserved or uncon-
served epitopes at all. Only five of the 21 alleles predicted
to bind more than four conserved epitopes were pre-
dicted to bind at least as many unconserved as conserved
epitopes. Individuals with these alleles - DRB1*1101,
0901, 1402, 1502, and 1602 - might also be less efficiently
protected by the Mtb72f vaccine.
Because Mtb72f is a polyprotein containing several
non-TB potential epitopes at the junction of the PPE18
and PepA proteins and at the N-terminus of the polypro-
tein, we investigated whether epitopes present in the
Mtb72f vaccine but not in the native PPE18 and PepA
proteins might misdirect the immune response upon
immunization. Fortunately, most of the alleles of concern
noted above did not bind any of the non-TB epitopes in
the vaccine, but DRB1*0302, 0403, 0411, and 1301 were
each predicted to bind to a median of one non-TB
epitope. This finding is of particular concern for
DRB1*0302, a common allele in South Africa, because it
was not predicted to bind any of the protective epitopes
(conserved or unconserved) in the vaccine. The DRB1-
mediated immune response to Mtb72f in people with this
allele might thus be misdirected against epitopes that are
found in the vaccine but not in TB and thus this portion
of the immune response would not be protective. As
South Africa is one of the sites for the Phase II clinical tri-
als of the Mtb72f vaccine, it would be beneficial to collect
immunological data from vaccine recipients in order to
determine whether the vaccine is effective in persons
with the DRB1*0302 allele.
While this analysis should be useful for assessing popu-
lation coverage of the Mtb72f vaccine, it is important to
recognize the limitations inherent in the use of epitope
prediction programs. No epitope prediction program is
perfectly accurate, and there is substantial disagreement
among the epitopes predicted by each program [14,15].
We increased the accuracy of our analysis by using multi-
ple prediction programs for each DRB1 allele when possi-
ble, but there are nevertheless likely to be differences
between the predicted and actual epitopes for many
alleles. However, as we obtained good agreement among
programs as far as which alleles were predicted to bind
relatively many or few vaccine epitopes, the lists of alleles
1302 14 (8) 6 Susceptible [53]; 
Protective [29,53]
Brazil Southeast Mulattos, Democratic 
Republic of the Congo, Ethiopia
1303 9 (5) 1 NK Democratic Republic of the Congo, 
Northeast India
1401 5 (3) 1 Susceptible [29] Southern China, Northern India, 
Philippines, Russian Nivkhi and Evenki, 
Udege, and Ulchi, Vietnamese Muong
1402 19 (8) 1 NK Brazil Xavantes, Guarani, and Terena; 
Russian Chukchi, Eskimos, Koryaks, 
Nivkhi, and Udege
1403 2 (0) 1 NK Chinese Drung, Russian Evenki and Kets
1404 3 (2) 1 NK China Naxi and Lisu, India (Delhi)
1405 10 (3) 1 NK Chinese Wa Population
1413 38 (19) 1 NK Brazil Guarani M bya population
1501 15 (9) 8 Susceptible [29,54,55] China, Hong Kong and Singapore, India, 
Indonesia, Russia (Siberia), Northeast 
Thailand
1502 12 (5) 2 Susceptible [29] Chinese Jino population, India, 
Indonesia, Philippines, Thailand, Vietnam
1503 15 (8) 1 NK Zimbabwe (Harare)
1504 6 (2) 1 NK Chinese Nu and Va populations
1602 17 (6) 1 NK Brazil Xavantes, Guarani, Kaingang, 
Terena, and Ticuna populations, Chinese 
Maonan and Miao populations, Northern 
Thailand, Vietnamse Muong
1Alleles of particular concern (median of four or fewer conserved vaccine epitopes) are highlighted with italics.
2N = number of programs able to predict epitope binding to that allele
3NK = None known
4Of the study populations included in the Allele*Frequencies in Worldwide Populations database [25]
Table 4: Epitope binding predictions for DRB1 alleles that are common in TB high-burden countries (Continued)
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Page 9 of 12and populations of concern would not likely be substan-
tially changed by improvements in the prediction pro-
grams or experimental confirmation.
Although we compared epitope predictions across
eight different programs, these programs are not per-
fectly comparable. Several of the programs, such as Vax-
ign, provided information on peptide affinity predictions
only for epitopes predicted to bind each allele. As we
could not obtain affinity information for peptides pre-
dicted not to bind, we were unable to evaluate the binding
threshold to which the prediction program was automati-
cally set. Furthermore, the binding cutoffs used by several
of the programs likely differ from the IC50 ≤ 500 nM cut-
off that we imposed on programs generating IC50 predic-
tions. However, as the number of epitopes predicted by
programs with non-IC50-based cutoffs generally though
not always fell within the range of programs that did use
the IC50 cutoff, it is unlikely that the differing thresholds
among programs severely skewed the results.
Finally, it should be noted that the HLA allele frequen-
cies in different populations [25] that were utilized to
generate the list of alleles of concern were in some cases
generated through only a few small studies. It is likely that
further study of HLA genotypes would alter our predic-
tions of which populations might be more or less effec-
tively protected by the Mtb72f vaccine.
Conclusions
We conclude that the Mtb72f vaccine may be less protec-
tive in certain populations that suffer from a high burden
of TB and thus that additional protective measures may
be needed in these populations in addition to this prom-
ising vaccine candidate. While the findings from this in
silico analysis should be verified with immunological
studies, this analysis complements in vitro and in vivo
experimentation by vastly expanding the range of host
and pathogen factors that can be examined and incorpo-
rating an analysis of many more genotypes than a labora-
tory or even clinical study could include. Furthermore,
this type of analysis can be used to aid rational selection
of populations in which to conduct clinical trials for vac-
cines. This method of vaccine evaluation could also be
usefully extended to other subunit vaccine candidates for
TB, as well as vaccine candidates for HIV and other dis-
eases, and might provide a means of comparing different
vaccines to select the best vaccine to use in a given popu-
lation. However, continued improvements to epitope pre-
diction software, refinement of programs to predict pre-
presentation epitope processing, and further study of the
HLA genotypes of world populations could help to
increase the accuracy and utility of such vaccine evalua-
tions.
Methods
Allele selection
Although both Class I and Class II-mediated T cell
immunity are important in M. tuberculosis infection, we
focused on alleles of the Class II MHC DRB1 gene for
several reasons. First, Class II MHC molecules are the
ones that interact with CD4+ T helper cells, which stimu-
late macrophages to kill phagocytosed pathogens. As M.
tuberculosis inhabits macrophages, CD4+ T cell-medi-
ated immunity is of particularly crucial importance for
preventing and clearing M. tuberculosis infection
(reviewed in [2]). DR alleles were examined because of
the relative abundance of data on epitope binding to DR
alleles; for TB more than 90% of known Class II M. tuber-
culosis epitopes bind to DR antigens [28]. Finally, the
DRB1 gene was studied because DRB1 proteins are typi-
cally expressed at five-fold greater levels than are the
DRB3, DRB4, or DRB5 genes [29]. To ensure high predic-
tion accuracy, our initial analysis focused on the twelve
DRB1 alleles for which epitope binding predictions were
available from at least four of the eight epitope prediction
programs used. These include DRB1*0101, 0301, 0401,
0404, 0405, 0701, 0802, 0901, 1101, 1301, 1302, and 1501.
In addition, for each population in the Allele*Frequencies
in Worldwide Populations database [25] that was from
the twenty-two TB high burden countries identified by
the WHO [26], we determined the three most common
DRB1 alleles in that population and evaluated epitope
binding predictions for each of these DRB1 alleles. These
additional alleles were DRB1*0102, 0302, 0403, 0411,
0801, 0803, 0804, 0807, 1001, 1201, 1202, 1303, 1401,
1402, 1403, 1404, 1405, 1413, 1502, 1503, 1504, and 1602.
Epitope prediction
Epitope prediction programs use several different types
of prediction algorithms, including matrix-based meth-
ods (e.g. the TEPITOPE matrices [30]), artificial neural
networks (e.g. NetMHCIIpan [11]), support vector
machine regression methods (e.g. SVRMHC [31,32]), and
partial least squares methods (e.g. MHCPred [33-35]). In
addition to these different methods, some programs (e.g.
MHC-BPS [36], NetMHCII [37]) can incorporate peptide
length as well as peptide sequence into their prediction of
peptide-MHC affinity. There is conflicting data as to
which epitope prediction program provides the most
accurate predictions for binding to each MHC molecule
[13,14], but consensus approaches have been shown to
increase prediction accuracy [15,16]. We therefore used
eight online epitope prediction programs to evaluate the
number of epitopes in the Mtb72f vaccine predicted to
bind each human MHC Class II molecule of interest. To
select programs for this study, a comprehensive list of the
more than a dozen freely available epitope prediction
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through a search of the literature. We then selected pro-
grams that either explicitly predicted which peptides
were predicted to bind each MHC molecule or predicted
the half maximal inhibitory concentration (IC50) for each
peptide, as binding predictions could be inferred directly
from the IC50 values using the criterion that binding pep-
tides usually have an IC50 ≤ 500 [38]. Because we required
discrimination of binding and non-binding peptides, sev-
eral MHC Class II epitope prediction programs that nei-
ther explicitly predicted binding peptides nor provided
an IC50 score for peptides, including SYFPEITHI,
MHC2Pred, and PeptideCheck, were excluded.
The remaining programs were screened to ensure that
each used a distinct epitope prediction algorithm. Further-
more, to maintain some consistency among alleles, we
used only programs that could predict binding to at least
three human Class II MHC alleles. MHC class II molecules
typically bind peptides of length 10-30. However, a 9 amino
acid binding core, or nonamer, is sufficient to bind to a
MHC class II molecule [39]. We included only programs
that either predicted only nonamer peptide binding or
explicitly predicted the nonamer core when predicting the
binding of longer peptides to ensure that the predictions
from each of the programs used could be directly com-
pared, since many of the epitope prediction programs
could predict binding only for nonamer sequences (Table
1). Most of these programs have been frequently used for
various types of epitope research; Vaxign is a recently
developed program of epitope prediction specifically tar-
geted for vaccine development [40].
Binding cutoffs were next determined for each pro-
gram. For programs that explicitly predict binding
epitopes (RankPep and Vaxign), the default cutoffs were
used. For programs that assigned IC50 or -logIC50 values
to each epitope (ARB, MHCPred, NetMHCII, NetMHCI-
Ipan, and SVRMHC), binders were assigned as those
epitopes with IC50 ≤ 500 (recommended in [38]). Finally,
for ProPred, the recommended criterion of classifying
peptides with binding scores within the top 3% of all nat-
ural peptides as probable binders was used [41].
Each portion of the Mtb72f polyprotein sequence [5],
PPE18 and the two sections of PepA, was entered sepa-
rately into each prediction program and epitope predic-
tions for the DRB1 alleles of interest were acquired.
Binding predictions were also generated for all potential
epitopes from the vaccine that were not in either of the
two original proteins, including epitopes at the junctions
of the two proteins in the polyprotein sequence and those
from the N-terminal poly-His tag.
Comparison of epitopes between vaccine and clinical 
strains
A previous study from our laboratory found that there
was substantial variation in the PPE18 sequences and
limited variations in the PepA sequences in a sample of
clinical isolates from Turkey and Arkansas compared to
those in the H37Rv laboratory reference strain [8]. In this
study, we examined the effect of this clinical sequence
variation on Mtb72f epitope binding. For each nonamer
amino acid residue sequence in each protein, the number
of unique clinical variants with a change in the nonamer
sequence or in the N- or C-terminal pentamer flanking
sequence was calculated. This epitope conservation data
was then combined with our epitope predictions to deter-
mine whether epitopes predicted to be immunogenic in a
certain DRB1 background would protect the host against
a wide range of clinical M. tuberculosis strains.
Data analysis
Epitope prediction and conservation data were imported
into SAS version 9.2 (SAS Institute, Cary, NC) and com-
piled to determine conservation of each predicted
epitope. Criteria for classifying epitopes as conserved or
unconserved were determined by finding local minima in
distributions of the proportions of clinical variant strains
in which each epitope was conserved. This process
resulted in a definition of unconserved epitopes as vac-
cine epitopes that were absent or mutated in three or
more of the twenty-seven clinical variants of the PPE18
antigen found previously among a total of 225 clinical iso-
lates obtained from Arkansas, United States and Malatya,
Turkey [8].
The numbers of PepA, PPE18, and unconserved PPE18
epitopes predicted to bind each DRB1 allele were calcu-
lated to find alleles to which particularly few epitopes
were predicted to bind. As all PepA nonamers were con-
sidered conserved, we did not analyze unconserved PepA
epitopes separately. With the exception of NetMHCIIpan,
each epitope prediction program could generate predic-
tions for only a subset of the twelve alleles studied, and
therefore a different subset of prediction programs was
used to predict epitope binding to each allele. To ensure
that any trends in the number of epitopes predicted to
bind each allele was not due solely to the different group
of prediction programs used to predict epitopes for each
allele, several methods of adjusting the epitope predic-
tions by the characteristics of the particular programs
used were attempted but were not found to alter the
observed trends (data not shown).
Further analyses were conducted to determine how
many of the twelve commonly-predicted DRB1 alleles
each epitope was predicted to bind. A consensus
approach was used to define promiscuous epitopes, with
an epitope considered "predicted to bind" to DRB1 alleles
DRB1*0101, 0401, 0404, 0405, 0701, 0901, 1101 and 1302
if at least half of the epitope prediction programs avail-
able for the allele in question predicted epitope binding.
For DRB1*0301, 0802, 1301, and 1501, there was reduced
agreement among programs and fewer epitopes pre-
dicted overall; therefore epitopes were considered "pre-
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Page 11 of 12dicted to bind" if at least 42% (1501), 33% (0301), or 25%
(0802, 1301) of the epitope prediction programs available
for that allele predicted that the epitope would bind.
The overall allele frequency of each DRB1 allele in TB-
endemic populations was also considered to determine
whether the Mtb72f vaccine would be equally effective in
all populations considered. We characterized each popu-
lation in a high burden TB country in the Allele*Frequen-
cies Database as being of great, moderate, or lesser
concern of reduced Mtb72f vaccine efficacy. Populations
of moderate concern were defined as those where two of
the three most common DRB1 alleles were predicted to
bind a median of four or fewer conserved vaccine
epitopes or the single most common DRB1 allele was
present at a frequency of greater than 0.275 (a local mini-
mum in the allele frequency distribution) and predicted
to bind a median of four or fewer conserved vaccine
epitopes. Populations for which all of the three most
common DRB1 alleles were predicted to bind a median of
four or fewer conserved vaccine epitopes or the single
most common DRB1 allele was present at a frequency of
greater than 0.495 (a local minimum in the allele fre-
quency distribution) and predicted bind a median of four
or fewer conserved vaccine epitopes were categorized as
populations of great concern. All other populations were
classified as populations of lesser concern.
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